https://sc75741inhibitor.com/h....igher-oxide-ion-cond
Mutations in IDH1, IDH2, and TET2 tend to be recurrently noticed in myeloid neoplasms. IDH1 and IDH2 encode isocitrate dehydrogenase isoforms, which usually catalyze the conversion of isocitrate to α-ketoglutarate (α-KG). Oncogenic IDH1/2 mutations confer neomorphic activity, causing the production of D-2-hydroxyglutarate (D-2-HG), a potent inhibitor of α-KG-dependent enzymes such as the TET methylcytosine dioxygenases. Provided their particular mutual exclu
Like
Comment
Share
